Aprea Therapeutics, Inc. (APRE) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 118.11K | 162.46K | 205.82K | 354.62K | 561.57K | 380.57K | 14.07K | 319.47K | 249.69K |
| Revenue Growth % | -100% | -100% | -100% | -78.97% | -57.31% | 1362.29% | 11% | 124.91% | - | - | - | - |
| Cost of Goods Sold | 5.43K | 0 | 0 | 1.91M | 2.48M | 2.36M | 2.85M | 2.56M | 1.6M | 2.05M | 2.12M | 2.2M |
| COGS % of Revenue | - | - | - | 1619% | 1528.39% | 1146.21% | 802.66% | 455.45% | 420.52% | 14534.2% | 664.42% | 882.16% |
| Gross Profit | -5.43K | 0 | 0 | -1.79M | -2.32M | -2.15M | -2.49M | -2M | -1.22M | -2.03M | -1.8M | -1.95M |
| Gross Margin % | - | - | - | -1519% | -1428.39% | -1046.21% | -702.66% | -355.45% | -320.52% | -14434.2% | -564.42% | -782.16% |
| Gross Profit Growth % | 99.77% | 100% | 100% | 10.12% | -90.24% | -5.99% | -38.19% | -2.21% | 2.92% | -282.31% | -61.34% | 71.33% |
| Operating Expenses | 3.42M | 2.64M | 3.12M | 1.59M | 1.76M | 1.07M | 1.61M | 1.85M | 1.93M | 1.64M | 1.72M | 1.7M |
| OpEx % of Revenue | - | - | - | 1349.3% | 1086.39% | 521.23% | 452.66% | 329.58% | 507.1% | 11675.42% | 538.31% | 680.33% |
| Selling, General & Admin | 1.81M | 1.64M | 1.48M | 1.59M | 1.76M | 1.07M | 1.61M | 1.85M | 1.93M | 1.64M | 1.72M | 1.7M |
| SG&A % of Revenue | - | - | - | 1349.3% | 1086.39% | 521.23% | 452.66% | 329.58% | 507.1% | 11675.42% | 538.31% | 680.33% |
| Research & Development | 1.61M | 1.01M | 1.64M | 1.91M | 2.48M | 2.36M | 2.85M | 2.56M | 1.6M | 2.05M | 2.12M | 2.2M |
| R&D % of Revenue | - | - | - | 1619% | 1528.39% | 1146.21% | 802.66% | 455.45% | 420.52% | 14534.2% | 664.42% | 882.16% |
| Other Operating Expenses | 0 | -3.34K | -1.85K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -1000K |
| Operating Income | -3.43M | -2.64M | -3.12M | -3.39M | -4.09M | -3.23M | -4.1M | -3.85M | -3.15M | -3.67M | -3.52M | -3.65M |
| Operating Margin % | - | - | - | -2868.3% | -2514.78% | -1567.43% | -1155.32% | -685.03% | -827.62% | -26109.62% | -1102.72% | -1462.5% |
| Operating Income Growth % | 16.04% | 18.07% | 23.91% | 11.94% | -29.71% | 12.21% | -16.3% | -5.35% | 31.86% | -38.59% | 16.13% | 96.29% |
| EBITDA | -3.42M | -2.64M | -3.11M | -3.38M | -4.08M | -3.22M | -4.09M | -3.84M | -3.14M | -3.67M | -3.52M | -3.65M |
| EBITDA Margin % | - | - | - | -2863.7% | -2511.44% | -1564.8% | -1153.79% | -684.08% | -826% | -26074.2% | -1102.28% | -1462.41% |
| EBITDA Growth % | 16.06% | 18.1% | 23.94% | 11.96% | -29.8% | 12.24% | -16.19% | -5.21% | 31.99% | -38.46% | 16.16% | 96.29% |
| D&A (Non-Cash Add-back) | 5.43K | 5.43K | 5.43K | 5.43K | 5.43K | 5.43K | 5.43K | 5.3K | 6.16K | 4.99K | 1.43K | 224 |
| EBIT | -3.43M | -2.64M | -3.12M | -3.39M | -4.09M | -3.23M | -4.1M | -3.85M | -3.15M | -3.67M | -3.52M | -3.65M |
| Net Interest Income | 134.78K | 118.66K | 150.67K | 178.03K | 204.73K | 274.63K | 348.74K | 382.37K | 283.4K | 310.29K | 321.21K | 336.22K |
| Interest Income | 134.78K | 118.66K | 150.67K | 178.03K | 204.73K | 274.63K | 348.74K | 382.37K | 283.4K | 310.29K | 321.21K | 336.22K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 142.5K | 187.46K | 144.98K | 148.9K | 152.92K | 331.25K | 313.25K | 376.87K | 339.58K | 231.68K | 318.33K | 392.58K |
| Pretax Income | -3.29M | -2.46M | -2.97M | -3.24M | -3.93M | -2.89M | -3.78M | -3.47M | -2.81M | -3.44M | -3.2M | -3.26M |
| Pretax Margin % | - | - | - | -2742.23% | -2420.65% | -1406.49% | -1066.99% | -617.92% | -738.39% | -24463.62% | -1003.08% | -1305.27% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -3.29M | -2.46M | -2.97M | -3.24M | -3.93M | -2.89M | -3.78M | -3.47M | -2.81M | -3.44M | -3.2M | -3.26M |
| Net Margin % | - | - | - | -2742.23% | -2420.65% | -1406.49% | -1066.99% | -617.92% | -738.39% | -24463.62% | -1003.08% | -1305.27% |
| Net Income Growth % | 16.39% | 15.17% | 21.44% | 6.66% | -39.95% | 15.93% | -18.08% | -6.47% | 35.84% | -40.99% | 20.38% | 96.68% |
| Net Income (Continuing) | -3.29M | -2.46M | -2.97M | -3.24M | -3.93M | -2.89M | -3.78M | -3.47M | -2.81M | -3.44M | -3.2M | -3.26M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.43 | -0.32 | -0.47 | -0.53 | -0.66 | -0.49 | -0.64 | -0.58 | -0.67 | -0.92 | -0.86 | -0.87 |
| EPS Growth % | 34.85% | 34.69% | 26.56% | 8.62% | 1.49% | 46.74% | 25.58% | 33.33% | 47.24% | 99.89% | 64.32% | 99% |
| EPS (Basic) | -0.43 | -0.32 | -0.47 | -0.53 | -0.66 | -0.49 | -0.64 | -0.58 | -0.67 | -0.92 | -0.86 | -0.87 |
| Diluted Shares Outstanding | 7.69M | 7.69M | 6.37M | 6.08M | 5.99M | 5.95M | 5.94M | 5.94M | 4.2M | 3.74M | 3.74M | 3.73M |
| Basic Shares Outstanding | 7.69M | 7.69M | 6.37M | 6.08M | 5.99M | 5.95M | 5.94M | 5.94M | 4.2M | 3.74M | 3.74M | 3.73M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |